Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992964 | 0.86 | ALDH1A1 (1.00) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL9121193 | 0.86 | ALDH1A1 (0.73) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL11791404 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TP53PTGS2HPGDKDM4E | |
| SCHEMBL112540 | 0.82 | ALDH1A1 (0.67) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL16642162 | 0.82 | ALDH1A1 (0.67) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL1415953 | 0.81 | TP53 (1.00) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL2988323 | 0.80 | ALDH1A1 (0.86) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL13381492 | 0.79 | ALDH1A1 (0.76) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| Isoniazid SCHEMBL28274529 | 0.79 | KDM4E (0.84) | ALDH1A1TP53MAOAMAOBPTGS2 | |
| SCHEMBL2477798 | 0.79 | GAA (0.69) | ALDH1A1TP53CA1CA9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2014174457-A1 | PYRAZOLE CARBOXYLIC ACID ANALOGUES AS ANTI-MYCOBACTERIAL DRUG CANDIDATES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-10-30 | — | — | WO | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| CN-101723941-A | “1,2,4” oxadiazole as a metabotropic glutamate receptor-5 modulator | ASTRAZENECA AB | 2010-06-09 | — | — | CN | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
| CN-101096368-A | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (SE) | 2008-01-02 | — | — | CN | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| CN-1984907-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-06-20 | — | — | CN | disclosed |
| CN-1918154-A | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (SE) | 2007-02-21 | — | — | CN | disclosed |
| CN-1894241-A | \"1, 2, 4\" oxadiazoles as modulators of metabotropic glutamate receptor-5 | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| CN-1826335-A | Process for producing 1,2, 4-triazole compound and intermediate therefor | FUJIYAKUHIN CO LTD (JP) | 2006-08-30 | — | — | CN | disclosed |
| US-4111944-A | SUBSTITUTED 1,2,4-TRIAZOLES | MERCK & CO., INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-3963731-A | TREATMENT OF GOUT AND HYPERURICEMIA | MERCK & CO., INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3947577-A | 1,2,4-TRIAZOLES | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | ALDH1A1 381/4885TP53 1233/4885MAOA 1268/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | ALDH1A1 4446/4885TP53 3681/4885MAOA 2448/4885 |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | ALDH1A1 302/4885TP53 2283/4885MAOA 1140/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | ALDH1A1 2740/4885TP53 3840/4885MAOA 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.